Sun Pharma and Organon File HSR, Awaiting Antitrust Clearance

Sun Pharma and Organon File HSR, Awaiting Antitrust Clearance

Sun Pharmaceuticals and Organon & Co. have submitted their Hart-Scott-Rodino premerger notification, with the antitrust waiting period scheduled to expire on June 22. This filing marks a significant step in their potential transaction. The $11.75 billion all-cash deal — Sun Pharma's largest cross-border acquisition to date — would reshape the women's health and biosimilars markets, adding a $6.2 billion revenue base to the Indian pharma giant's global portfolio.

Key Takeaways

• Sun Pharma Organon filed HSR on May 21, triggering the mandatory 30-day antitrust review clock under the Hart-Scott-Rodino Act.
• The waiting period expires June 22 — the earliest date the transaction can close absent a second request from the FTC or DOJ.
• The definitive agreement values Organon at $11.75 billion in an all-cash transaction, with both boards having approved the deal on April 26, 2026.
• Morgan Stanley, Goldman Sachs, and Sullivan & Cromwell are advising Organon on the cross-border acquisition.
• The deal targets Sun Pharma's expansion into women's health biopharma and biosimilars, adding a $6.2 billion revenue base to its global portfolio.

What the Hart-Scott-Rodino Filing Means for the Deal Timeline

Sun Pharmaceuticals and Organon & Co. officially filed their Hart-Scott-Rodino premerger notification with the Federal Trade Commission and the Department of Justice on May 21. The HSR Act requires parties to transactions exceeding specified thresholds to observe a waiting period — typically 30 days — during which antitrust agencies assess whether the proposed combination would harm competition.

In this case, the waiting period runs through June 22, as confirmed by Organon in a US securities filing. That expiration date represents the earliest point at which the parties could legally close. If the FTC or DOJ issues a second request for additional information before June 22, the review timeline extends substantially and signals that regulators have identified potential competitive concerns warranting deeper scrutiny.

The filing itself confirms that the parties have moved beyond the non-binding offer stage. Sun Pharma had previously submitted a non-binding proposal to acquire the US-based women's health company, and the two sides have since executed a definitive merger agreement dated April 26, 2026.

Why Is Sun Pharma Pursuing an $11.75 Billion Bet on Organon?

Sun Pharma's pursuit of Organon represents a calculated bet to transform its global portfolio. Organon generated approximately $6.2 billion in annual sales, with established positions in women's health, biosimilars, and established brands — therapeutic areas where Sun Pharma has sought deeper footholds. The combined entity would command significant scale across both emerging and developed markets.

For BD teams tracking competitive dynamics, the deal signals a potential shift in how large generic and specialty pharma companies approach portfolio diversification. Rather than building women's health pipelines organically, Sun Pharma is acquiring an entire commercial and R&D infrastructure in a single transaction. The $11.75 billion price tag — at the lower end of the initially reported $10–14 billion financing range — suggests disciplined capital allocation even for a deal of this magnitude.

Investors should watch for two signals in the coming weeks. First, whether the HSR waiting period expires without a second request, which would indicate a relatively clean antitrust review. Second, the proxy statement timeline — Organon shareholders must still vote on the merger, and the SEC must clear the proxy materials before that vote can occur.

Who Are the Advisors on the Sun Pharma–Organon Deal?

Organon has assembled a heavyweight advisory team for the transaction. Morgan Stanley & Co. LLC is serving as lead financial advisor, with Goldman Sachs & Co. LLC acting as additional financial advisor. Sullivan & Cromwell LLP is legal advisor to Organon, and Cyril Amarchand Mangaldas is advising on India-related legal matters. The caliber of advisors reflects both the complexity of a cross-border acquisition of this size and the regulatory scrutiny it is likely to attract.

Did Sun Pharma Place a Non-Binding Offer to Acquire Organon?

Yes. Sun Pharmaceutical Industries Ltd submitted a non-binding offer to acquire Organon for an all-cash deal, securing $10–14 billion in acquisition financing. That initial overture has since matured into a definitive agreement, with both boards approving the transaction. The non-binding phase allowed Sun Pharma to conduct due diligence and negotiate terms before committing to the $11.75 billion binding price.

How Does This Deal Reshape the Women's Health and Biosimilars Markets?

The combination would create a company with combined annual sales of roughly $12.4 billion, pairing Sun Pharma's emerging-market manufacturing strength and specialty portfolio with Organon's established commercial infrastructure in women's health and biosimilars. Competitors in both therapeutic areas should assess whether the combined entity's scale advantages — in procurement, distribution, and R&D investment — could shift pricing dynamics or partnership opportunities.

For biosimilars specifically, the deal could accelerate Sun Pharma's entry into the US and European biosimilar markets, where Organon has already secured approvals and built commercial relationships. In women's health, Organon's contraceptive and fertility portfolio would give Sun Pharma a ready-made specialty franchise that would take years to replicate through internal development.

Frequently Asked Questions

What Comes Next: Regulatory Outlook and Key Dates

The immediate catalyst is the June 22 HSR expiration. If the waiting period lapses without a second request, the parties gain antitrust clearance and can proceed toward closing, subject to the remaining conditions. A second request would push the timeline out by several months and could force divestitures or other remedies.

Beyond antitrust, the deal requires Organon shareholder approval and SEC clearance of the proxy statement. BD teams and investors should monitor SEC filings for the preliminary proxy, which will contain detailed deal terms, financial projections, and the board's recommendation. The successful closing of this transaction would mark one of the largest cross-border pharma acquisitions of 2026 and could trigger further consolidation in the women's health and biosimilars sectors.

Related coverage

• Organon (OGN) to be Acquired by Sun Pharma for $14.00 Cash per Share
• Opinion: The Virtual End of the Doctor's Office Waiting Room
• Understanding Computer Software Assurance (CSA) and Its Benefits for Pharma